康惠製藥(603139.SH):收到陝西證監局警示函
格隆匯10月18日丨康惠製藥(603139.SH)公佈,收到中國證券監督管理委員會陝西監管局下發的《關於對陝西康惠製藥股份有限公司及王延嶺、董娟採取出具警示函措施的決定》,經查,公司存在信息披露不準確、不完整情形:公司於10月13日、10月16日針對孫公司陝西友幫是否可生產降糖/減肥藥物司美格魯肽、替泊爾肽中間體的問題前後回覆不一致,信息披露不準確、不完整,不符合《上市公司信息披露管理辦法》相關規定。根據《辦法》第五十一條第二款規定,公司董事長兼總經理王延嶺、董事會祕書董娟對前述事項負有主要責任。根據《辦法》第五十二條規定,我局決定對公司及王延嶺、董娟採取出具警示函的行政監管措施。你們應認真汲取教訓,切實加強信息披露方面證券法律法規學習,在收到本決定書之日起十五個工作日內向我局提交書面報吿。下一步,我局將根據正在開展的專項核查情況決定是否採取進一步措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.